Personalized Medicine. History, current state and future directions
Abstract
The review assesses history of personalized approach in medicine, terminology and definitions and current situation in personalized medicine in the world. Major fields of implementation, classification, advantages and practical barriers are also discussed as well as future perspectives.
About the Authors
E. V. Shlyakhto
Almazov National Medical Research Centre; World-Class Research Centre for Personalized Medicine
Russian Federation
Russian Federation
Shlyakhto Evgeny V., MD, PhD, Dr. Sc., Professor, Academician of the Russian Academy of Science, Director; Director
Saint Petersburg
A. O. Konradi
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Konradi Alexandra O., MD, Dr. Sc., Professor, Corresponding Member RAS, Deputy General Director for Research, Head of the Research Department of Arterial Hypertension, Head of the Department of Management Organization and Health Economics, Institute of Medical Education
Akkuratova str. 2, Saint Petersburg, Russia, 197341
References
1. Schwab K. The fourth industrial revolution. World Economic Forum. New York, NY: Crown Publishing Group, 2017.
2. Personalized medicines fact sheet. Genes to personalized medicines. Progress from the National Institute of General Medical Sciences. National Institute of Health. https://www.nih.gov/about-nih/what-wedo/nih-turning-discovery-into-health/personalizedmedicine (29 August 2021).
3. Alyass A, Turcotte M, Meyre D. From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med Genomics. 2015;8: 33. DOI: 10.1186/s12920-015-0108-y.
4. Strategy of scientific and technological development of the Russian Federation (approved by the Decree of the President of the Russian Federation of December 1, 2016 No. 642). In Russian [Стратегия науч- но-технологического развития Российской Федерации (утверждена Указом Президента Российской Федерации от 1 декабря 2016 г. № 642)].
5. National Research Council (US) Committee on a framework for developing a new taxonomy of disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington (DC): National Academies Press (US); 2011. PMID: 22536618.
6. Kirchhof P, Sipido KR, Cowie MR, et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J. 2014;35(46):3250–3257. DOI: 10.1093/eurheartj/ehu312.
7. Senn S. Mastering variation: variance components and personalised medicine. Stat Med. 2016;35(7):966–977. DOI: 10.1002/sim.6739.
8. Pan S, Knowles JW. Exploring predisposition and treatment response — the promise of genomics. Prog Cardiovasc Dis. 2012;55(1):56–63. DOI: 10.1016/j.pcad.2012.04.006.
9. Hwang J, Christensen CM. Disruptive innovation in health care delivery: a framework for business-model innovation. Health Aff (Millwood). 2008;27(5):1329–1335. DOI: 10.1377/hlthaff.27.5.1329.
10. Joyner MJ, Prendergast FG. Chasing Mendel: five questions for personalized medicine. J Physiol. 2014;592(Pt 11):2381–2388. DOI: 10.1113/jphysiol.2014.272336.
11. Mayo clinic staff. Pharmacogenomics: when medicine gets personal. Mayo Foundation for Medical Education and Research (MFMER). July 16, 2010. 12. Jain KK. Personalized medicine. Waltham: Decision Resources Inc; 1998.
12. Garrod AE. The inborn factors in disease. London: Oxford University Press; 1931.
13. Kalow W. Familial incidence of low pseudocholinesterase level. Lancet. 1956;268(6942):576–577.
14. Motulsky AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc. 1957;165(7):835–837. DOI: 10.1001/jama.1957.729802500100.
15. Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: Saunders; 1962.
16. Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor Symp Quant Biol. 1986;51 Pt 1:263–273. DOI: 10.1101/sqb.1986.051.01.032.
17. O’Donnell CJ, Nabel EG. Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era. Circ Cardiovasc Genet. 2008;1(1):51–57. DOI: 10.1161/CIRCGENETICS.108.813337.
18. Caulfield BM, Donnelly SC. What is Connected Health and why will it change your practice? QJM. 2013;106(8):703–707. DOI: 10.1093/qjmed/hct114.
19. Jain KK. Personalized medicine. Springer New York Heidelberg Dordrecht London. Springer Science+Business Media New York; 2015.
20. Offit K. Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130(1):3–14. DOI: 10.1007/s00439-011-1028-3.
21. Offit K. Genomic profiles for disease risk: predictive or premature? JAMA. 2008;299(11):1353–1355. DOI: 10.1001/jama.299.11.1353.
22. Sherkow JS, Greely HT. The future of gene patents and the implications for medicine. JAMA Intern Med. 2013;173(17):1569–1570. DOI: 10.1001/jamainternmed.2013.10153.
Review
For citations:
Shlyakhto E.V., Konradi A.O. Personalized Medicine. History, current state and future directions. Russian Journal for Personalized Medicine. 2021;1(1):6-20.
Views:
1200
Email this article 